Exposure Station: Shandong Provincial Drug Administration reported that 11 batches of drugs were not qualified

"Notice" shows that marked Ganzhou Zhongqiang Chinese medicine tablets Co., Ltd. (hereinafter referred to as Luzhou Zhongqiang) production of a batch of grass wu (production lot number: 170301) nature does not meet the requirements.
Just four days after the Shandong Provincial Drug Administration issued the Notice, Zhangzhou Zhongqiang was again named by the Guizhou Provincial Drug Administration Drug Quality Announcement (Drug Sampling Information Notice) (No. 4 of 2020) (Total No. 42) as a batch of Jinlong bile (production batch number: 190701) produced by Zhongqiang in Zhangzhou.
reporter logged into the China Health Media Group Food and Drug Public Opinion Monitoring System inquiry found that The quality of products in Zhangzhou Zhongqiang has been repeatedly informed by the local drug regulatory departments.
November 6, 2020, the Zhejiang Provincial Drug Administration issued the 2nd issue of Zhejiang Province drug quality spot check inspection notice notice, indicating that the labeling of the production enterprises as The first batch of Zhongqiang in Zhangzhou before Hu (production lot number: 180601) content determination does not meet the requirements.
August 10, 2020, the Jiangsu Provincial Drug Administration issued the Notice on the Quality of Drugs No. 2 of 2020 in Jiangsu Province, which stated that the first batch of dragon bile (production lot number: 190601) marked as produced by Zhongqiang in Zhangzhou did not comply with the regulations.
It is worth noting that as early as February 11, 2020, Anhui Provincial Drug Administration issued a notice that the Luzhou Municipal Market Supervision Bureau of Ganzhou Zhongqiang to carry out drug GMP (flight) inspection, found that the enterprise has serious violations of drug GMP behavior, drug production there are quality and safety risks and hidden dangers.
order to control the quality and safety risks and hidden dangers of drugs, Anhui Provincial Drug Administration decided to suspend the production of Chinese medicine tablets in Zhongqiang, Zhangzhou.
for this time by the Shandong Provincial Drug Administration informed that the drug does not meet the requirements, the reporter called Zhangzhou Zhongqiang, a male person in charge said the matter is not clear.
reporter asked whether the company is now back to production, the person in charge said: "Not yet."
company has carried out a full range of rectification and submitted to the regulatory authorities a number of rectification plans, but has not yet resumed production.
" According to the Notice, another two batches of chemical drugs and one batch of Chinese medicine do not meet the requirements.
In addition, 7 batches of Chinese medicine tablets produced by 7 enterprises, including Inner Mongolia Pukang Pharmaceutical Co., Ltd., were found to be non-compliant, but Inner Mongolia Pukang Pharmaceutical Co., Ltd. said it had not sold the inspected batch products directly to the sampled units.
The Notice shows that the relevant drug regulatory departments have taken control measures such as seizure, seizure, suspension of sales and product recall of non-compliant products, and have seriously investigated and dealt with the relevant production enterprises (preparation units) and sampling units in accordance with relevant laws and regulations.
(Reporter Pang Xue, intern reporter Yu Ruyu)